Zibotentan. Endothelin ETA receptor antagonist oncolytic

Drugs of the Future

Volumn 34, Issue 8, 2009, Pages 624-633

  James, Nicholas D ^a   Growcott, Jim W ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATRASENTAN; BISPHOSPHONIC ACID DERIVATIVE; CYTOCHROME P450 3A4; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; FOCAL ADHESION KINASE; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N (3 METHOXY 5 METHYL 2 PYRAZINYL) 2 [4 (1,3,4 OXADIAZOL 2 YL)PHENYL] 3 PYRIDINESULFONAMIDE; PACLITAXEL; PAMIDRONIC ACID; PLACEBO; PROSTATE SPECIFIC ANTIGEN; RIFAMPICIN; SEX HORMONE; STEROID; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; BONE METASTASIS; BRAIN HEMORRHAGE; BRAIN METASTASIS; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER SURVIVAL; CAUCASIAN; CELL INVASION; CELL PROLIFERATION; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BINDING; DRUG EFFECT; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG SPECIFICITY; DRUG SYNTHESIS; DRUG TOLERABILITY; DYSPNEA; ENZYME ACTIVATION; FATIGUE; HEADACHE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; JAPANESE; LOW DRUG DOSE; METASTASIS; NAUSEA AND VOMITING; NOSE CONGESTION; OVERALL SURVIVAL; PERIPHERAL EDEMA; PROSTATE CANCER; RACE DIFFERENCE; REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SOFT TISSUE METASTASIS; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; VASODILATATION; VOMITING;

EID: 84930540177     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2009.034.08.1400202     Document Type: Review

References (50)

1. Brear, C., Hogan, P., Montgomery, F. (AstraZeneca AB). Ethanolamine salt of N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazole-2-yl]phenyl) pyridine3-sulphonamide. WO 2007010235.
2. Bradbury, R.H., Butlin, R.J., James, R. (AstraZeneca plc). N-Heteroarylpyridinesulfonamide derivatives and their use as endothelin antagonists. EP 0832082, JP 1999509175, US 6060475, US 6258817, WO 1996040681.
3. Kamangar, F., Dores, G.M., Anderson, W.F. Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006, 24(14): 2137-50.
4. Kasper, S., Cookson, M.S. Mechanisms leading to the development of hormone-resistant prostate cancer. Urol Clin North Am 2006, 33(2): 201-10, vii.
5. Petrylak, D.P., Tangen, C.M., Hussain, M.H. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004, 351(15): 1513-20.
6. Petrylak, D. Therapeutic options in androgen-independent prostate cancer: Building on docetaxel. BJU Int 2005, 96(Suppl. 2): 41-6.
7. Tannock, I.F., de Wit, R., Berry, W.R. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351(15): 1502-12.
8. James, N.D., Bloomfield, D., Luscombe, C. The changing pattern of management for hormone-refractory, metastatic prostate cancer. Prostate Cancer Prostatic Dis 2006, 9(3): 221-9.
9. Hamamoto, D.T., Khasabov, S.G., Cain, D.M., Simone, D.A. Tumor-evoked sensitization of C nociceptors: A role for endothelin. J Neurophysiol 2008, 100(4): 2300-11.
10. Barton, M., Yanagisawa, M. Endothelin: 20 Years from discovery to therapy. Can J Physiol Pharmacol 2008, 86(8): 485-98.
11. Bagnato, A., Rosanò, L. The endothelin axis in cancer. Int J Biochem Cell Biol 2008, 40(8): 1443-51.
12. Nelson, J.B., Hedican, S.P., George, D.J., Reddi, A.H., Piantadosi, S., Eisenberger, M.A., Simons, J.W. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995, 1(9): 944-9.
13. Nelson, J.B., Chan-Tack, K., Hedican, S.P., Magnuson, S.R., Opgenorth, T.J., Bova, G.S., Simons, J.W. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res 1996, 56(4): 663-8.
14. Nelson, J.B., Lee, W.H., Nguyen, S.H. et al. Methylation of the 5′ CpC island of the endothelin B receptor gene is common in human prostate cancer. Cancer Res 1997, 57(1): 35-7.
15. Yegnasubramanian, S., Kowalski, J., Gonzalgo, M.L. et al. Hypermethylation of CpC islands in primary and metastatic human prostate cancer. Cancer Res 2004, 64(6): 1975-86.
16. Godara, G., Pecher, S., Jukic, D.M., D'Antonio, J.M., Akhavan, A., Nelson, J.B., Pflug, B.R. Distinct patterns of endothelin axis expression in primary prostate cancer. Urology 2007, 70(1): 209-15.
17. Godara, G., Cannon, G.W., Cannon, G.M. Jr., Bies, R.R., Nelson, J.B., Pflug, B.R. Role of endothelin axis in progression to aggressive phenotype of prostate adenocarcinoma. Prostate 2005, 65(1): 27-34.
18. Gohji, K., Kitazawa, S., Tamada, H., Katsuoka, Y., Nakajima, M. Expression of endothelin receptor a associated with prostate cancer progression. J Urol 2001, 165(3): 1033-6.
19. Nelson, J., Bagnato, A., Battistini, B., Nisen, P. The endothelin axis: Emerging role in cancer. Nat Rev Cancer 2003, 3(2): 110-6.
20. Okazawa, M., Shiraki, T., Ninomiya, H., Kobayashi, S., Masaki, T. Endothelin-induced apoptosis of A375 human melanoma cells. J Biol Chem 1998, 273(20): 12584-92.
21. Fukuroda, T., Fujikawa, T., Ozaki, S., Ishikawa, K., Yano, M., Nishikibe, M. Clearance of circulating endothelin-1 by ETB receptors in rats. Biochem Biophys Res Commun 1994, 199(3): 1461-5.
22. Carducci, M.A., Padley, R.J., Breul, J. et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: A randomized, phase II, placebo-controlled trial. J Clin Oncol 2003, 21(4): 679-89.
23. Carducci, M.A., Saad, F., Abrahamsson, P.A. et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 2007, 110(9): 1959-66.
24. Beer, T.M., Ryan, C.W. The hazards of intermediate endpoints. Cancer 2007, 110(9): 1877-9.
25. Dawson, N.A. Targeted therapy in prostate cancer - Are we our own worst enemy? Cancer 2008, 113(9): 2376-8.
26. Bradbury, R.H., Bath, C., Butlin, R.J. et al. New non-peptide endothelin-A receptor antagonists: Synthesis, biological properties, and structure-activity relationships of 5-(dimethylamino)-N-pyridyl-,-N-pyrimidinyl- ,-N-pyridazinyl-, and -N-pyrazinyl-1-nophthalenesulfonamides. J Med Chem 1997, 40(6): 996-1004.
27. Stensland, B., Roberts, R.J. N-(3-Methoxy-5-methylpyrazin-2-yl)-2-[4- (1,3,4-oxadiazol-2-yl)phenyl]pyridine-3-sulfonamide (ZD4054 Form 1). Acta Crystallogr Section E Structure Rep 2004, 60: o1817-9.
28. Morris, C.D., Rose, A., Curwen, J., Hughes, A.M., Wilson, D.J., Webb, D.J. Specific inhibition of the endothelin A receptor with ZD4054: Clinical and pre-clinical evidence. Br J Cancer 2005, 92(12): 2148-52.
29. Growcott, J.W. Preclinical anticancer activity of the specific endothelin A receptor antagonist ZD40S4. Anticancer Drugs 2009, 20(2): 83-8.
30. Pflug, B.R., McHugh, K., D'Antonio, J.M., Bocola-Mavar, E., Curwen, J., Growcott, J.W., Nelson, J.B. Defining the basis of an operational model for enhanced efficacy of combination therapy using an endothelin receptor antagonist and chemotherapeutic agents. Mol Cancer Ther 2007, 6: Abst A287.
31. Rosano, L., Cianfrocca, R., Masi, S. et al. Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis. Proc Natl Acad Sci U S A 2009, 106(8): 2806-11.
32. Wülfing, P., Smollich, M., Gotte, M., Fischgrabe, J., Radke, I., Chen, S., Kiesel, L. ZD4054, a selective endothelin A receptor antagonist, reduces breast cancer cell migration and invasion and exhibits additive effects with aromatase inhibitors and fulvestrant. Mol Cancer Ther 2007, 6: Abst A275.
33. Williams, E.D., Thompson, E.W., Sreedharan, D., Brooks, N., Curwen, J., Growcott, J.W. The combination of a specific endothelin A receptor antagonist ZD4054 and submaximal bisphosphonate Pamidronate prevents bone metastasis. Eur J Cancer Suppt [18th EORTC-NCI-AACR Symp Mol Targets Cancer Ther (Nov 7-10, Prague) 2006] 2006, 4(12): Abst 36.
34. Williams, E.D., Thompson, E.W., Sreedharan, D., Brooks, N., Curwen, J., Growcott, J.W. The combination of the specific endothelin A receptor antagonist ZD4054 and submaximal bisphosphonate pamidronate prevents soft-tissue metastasis. Mol Cancer Ther 2007, 6: Abst A271.
35. A receptor antagonist ZD40S4 reduces tumour-induced angiogenesis in a preclinical model. 10th Int Conf Endothelin (ET-10) (Sept 16-19, Bergamo) 2007, Abst O-56.
36. Bagnato, A., Spinella, F., Rosano, L. Emerging role of the endothelin axis in ovarian tumor progression. Endocr Relat Cancer 2005, 12(4): 761-72.
37. Iglarz, M., Silvestre, J.S., Duriez, M., Henrion, D., Levy, B.I. Chronic blockade of endothelin receptors improves ischemia-induced angiogenesis in rat hindlimbs through activation of vascular endothelial growth factor-no pathway. Arterioscler Thromb Vasc Biol 2001, 21(10): 1598-603.
38. Wulfing, P., Kersting, C., Tio, J. et al. Endothelin-1-, endothelin-A-, and endothelin-B-receptor expression is correlated with vascular endothelial growth factor expression and angiogenesis in breast cancer. Clin Cancer Res 2004, 10(7): 2393-400.
39. Rosanò, L., Di Castro, V., Spinella, F., Nicotra, M.R., Natali, P.G., Bagnato, A. ZD40S4, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo. Mol Cancer Ther 2007, 6(7): 2003-11.
40. Rosanò L., Di Castro, V., Spinella, F., Tortora, G., Nicotra, M.R., Natali, P.G., Bagnato, A. Combined targeting of endothelin A receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity. Cancer Res 2007, 67(13): 6351-9.
41. Clarkson-Jones, J., Kenyon, A., Kemp, J. et al. Metabolism of [14C]-ZD4054 in healthy volunteers. Eur J Cancer Suppl [14th Eur Cancer Conf (ECCO) (Sept 23-27, Barcelona) 2007] 2007, 5(4): Abst 724.
42. Ranson, M., Usami, M., Maruoka, M. et al. The pharmacokinetic and tolerability profile of once-daily oral ZD40S4 in Japanese and Caucasian patients with hormone-refractory prostate cancer. Eur J Cancer Suppl [14th Eur Cancer Conf (ECCO) (Sept 23-27, Barcelona) 2007] 2007, 5(4): Abst 718.
43. Schelman, W.R., Liu, G., Wilding, C., Morris, T., Phung, D., Dreicer, R. A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer. Invest New Drugs 2009, Epub ahead of print.
44. Spratt, J.C., Goddard, J., Patel, N., Strachan, F.E., Rankin, A.J., Webb, D.J. Systemic ETA receptor antagonism with BQ-123 blocks ET-1 induced forearm vasoconstriction and decreases peripheral vascular resistance in healthy men. Br J Pharmacol 2001, 134(3): 648-54.
45. Strachan, F.E., Spratt, J.C., Wilkinson, I.B., Johnston, N.R., Gray, G.A., Webb, D.J. Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men. Hypertension 1999, 33(1, Pt. 2): 581-5.
46. Carducci, M.A., Nelson, J.B., Bowling, M.K. et al. Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: Safety and pharmacokinetics. J Clin Oncol 2002, 20(8): 2171-80.
47. Zonnenberg, B.A., Groenewegen, C., Janus, T.J. et al. Phase I dose-escalation study of the safety and pharmacokinetics of atrasentan: An endothelin receptor antagonist for refractory prostate cancer. Clin Cancer Res 2003, 9(8): 2965-72.
48. James, N.D., Caty, A., Borre, M. et al. Safety and efficacy of the specific endothelin A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: A double-blind, placebo-controlled, randomized, phase II trial. Eur Urol 2009, 55(5): 1112-23.
49. Scher, H.I., Halabi, S., Tannock, I. et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Croup. J Clin Oncol 2008, 26(7): 1148-59.
50. Swaisland, H., Oliver, S., Morris, T. et al. Clinical drug interactions with ZD4054 in healthy, male volunteers. 1st Eur Multidisciplinary Meet Urol Cancers (Nov 2-4, Barcelona) 2007, Abst P84.